Table 1.
Baseline Demographics
| Baseline Characteristic | CD4 <50 cells/μL | CD4 50–99 cells/μL | CD4 ≥100 cells/μL | P valuea | |||
|---|---|---|---|---|---|---|---|
| Cohort, n | 540 | 133 | 63 | .11 | |||
| COAT Trial 2010–13, n (%) | 128 (23.7) | 47 (35.3) | 22 (34.9) | ||||
| ASTRO-CM Trial 2013–17, n (%) | 412 (76.3) | 86 (64.7) | 41 (65.1) | ||||
| Age, y median (IQR) | 540 | 35 (29–40) | 133 | 36 (30–42) | 63 | 35 (30–41) | .14 |
| Men, n (%) | 336 (62.2) | 63 (47.4) | 32 (50.8) | .15 | |||
| Glasgow Coma Scale <15, n (%) | 539 | 208 (38.6) | 133 | 55 (41.4) | 63 | 33 (52.4) | .03 |
| Temperature, ⁰C median (IQR) | 532 | 36.5 (35.9–37.2) | 131 | 36.5 (36.1–37.3) | 63 | 36.8 (36.0–37.7) | .09 |
| Seizures, n (%) | 540 | 22 (4.1) | 133 | 5 (3.8) | 63 | 1 (1.6) | .35 |
| Tuberculosis diagnosis (any site), n (%) | 523 | 87 (16.6) | 130 | 29 (22.3) | 59 | 13 (22.0) | .38 |
| Tuberculosis meningitis, n (%) | 540 | 4 (0.7) | 133 | 2 (1.5) | 63 | 1 (1.6) | .57 |
| CD4 cell count/μL, median (IQR) | 540 | 10 (5–21) | 133 | 72 (59–79) | 63 | 166 (115–234) | |
| On ART, n (%) | 539 | 174 (32.3) | 133 | 52 (39.1) | 62 | 27 (43.5) | .16 |
| Days on ART,b median (IQR) | 174 | 373 (44–1421) | 52 | 109 (34–987) | 27 | 88 (42–517) | .09 |
| CSF (baseline) | |||||||
| Opening pressure, cmH2O median (IQR) | 481 | 27 (18–41) | 110 | 21 (15–34) | 53 | 24 (18–36) | .01 |
| CSF white cells/μL, median (IQR) | 486 | <5 (<5–30) | 122 | 25 (<5–130) | 57 | 45 (<5–235) | <.001 |
| CSF white cells <5/μL, n (%) | 486 | 321 (66.0) | 122 | 49 (40.2) | 57 | 21 (36.8) | <.001 |
| Sterile CSF culture, n (%) | 523 | 14 (2.7) | 129 | 18 (14.0) | 61 | 12 (19.7) | <.001 |
| Quantitative culture,c median (IQR) | 509 | 5.0 (4.1–5.6) | 111 | 4.3 (2.8–5.2) | 49 | 3.9 (3.0–4.7) | <.001 |
Abbreviations: ART, antiretroviral therapy; ASTRO-CM, Adjunctive Sertraline for Treatment of Cryptococcal Meningitis; COAT, Cryptococcal Optimal ART Timing trial; CSF, cerebrospinal fluid; IQR, interquartile range.
a Χ 2 or Wilcoxon test as appropriate.
b Among those currently on ART.
c Among those with a nonsterile CSF culture.